Drug Search Results
More Filters [+]

DWJ-1521

Alternative Names: dwj-1521, dwj 1521, dwj1521
Latest Update: 2021-06-10
Latest Update Note: Clinical Trial Update

Product Description

Daewoong is investigating DWJ-304 , a sodium/glucose cotransporter 2 (SGLT-2) inhibitor, for treating type 2 diabetes.

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DWJ-1521

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DW_DWJ1521101

P1

Unknown status

Healthy Volunteers

2021-06-30

28%

Recent News Events

Date

Type

Title